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A bs tr ac t
Background
The effect of intensified platelet inhibition for patients with unstable angina or myo-
cardial infarction without ST-segment elevation who do not undergo revasculariza-
tion has not been delineated.
Methods
In this double-blind, randomized trial, in a primary analysis involving 7243 patients 
under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment 
with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis 
involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 
75 mg of clopidogrel.
Results
At a median follow-up of 17 months, the primary end point of death from cardio-
vascular causes, myocardial infarction, or stroke among patients under the age of 
75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel 
group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 
to 1.05; P = 0.21). Similar results were observed in the overall population. The pre-
specified analysis of multiple recurrent ischemic events (all components of the pri-
mary end point) suggested a lower risk for prasugrel among patients under the age of 
75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P = 0.04). Rates of severe and intra-
cranial bleeding were similar in the two groups in all age groups. There was no sig-
nificant between-group difference in the frequency of nonhemorrhagic serious ad-
verse events, except for a higher frequency of heart failure in the clopidogrel group.
Conclusions
Among patients with unstable angina or myocardial infarction without ST-segment el-
evation, prasugrel did not significantly reduce the frequency of the primary end point, 
as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by 
Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.)
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Clinical-practice guidelines for pa-tients with acute coronary syndromes con-sisting of unstable angina or myocardial 
infarction without ST-segment elevation recom-
mend a strategy of early invasive management (an-
giography within 48 to 72 hours with provisional 
revascularization) for patients at moderate to high 
risk.1,2 However, analyses from clinical trials and 
national registries have shown that many such pa-
tients are treated medically without revasculariza-
tion and that such patients have poorer long-term 
cardiovascular outcomes than those who undergo 
revascularization.3-6 Even though patients with 
acute coronary syndromes who receive only med-
ical therapy have an increased-risk profile, they 
have been underrepresented in large-scale, con-
temporary, randomized trials.7-9
Given the previously demonstrated benefits of 
prasugrel versus clopidogrel (both thienopyridine 
inhibitors of the platelet P2Y12 receptor) among 
patients undergoing percutaneous coronary in-
tervention (PCI), we evaluated whether aspirin 
plus prasugrel is superior to aspirin plus clo pid-
o grel for long-term therapy in patients with un-
stable angina or myocardial infarction without 
ST-segment elevation who were under the age of 
75 years.9 We also undertook a concomitant and 
exploratory assessment of a lower prasugrel dose 
for patients 75 years of age or older.
Me thods
Study Design
The Targeted Platelet Inhibition to Clarify the 
Optimal Strategy to Medically Manage Acute 
Coronary Syndromes (TRILOGY ACS) study was a 
randomized, double-blind, double-dummy, active-
control, event-driven trial. The study design has 
been described previously,10 and the protocol is 
available with the full text of this article at NEJM 
.org. The executive and steering committees, which 
included academic investigators and representa-
tives of the sponsor (Eli Lilly and Daiichi Sankyo), 
designed the study and supervised its conduct. (A 
complete list of committee members is provided 
in the Supplementary Appendix, available at NEJM 
.org.) An independent data and safety monitor-
ing board evaluated the safety of patients with 
semiannual meetings during the trial. Study data 
were collected and managed by Quintiles. Statis-
tical analyses were performed independently by 
the academic coordinating center at the Duke 
Clinical Research Institute. The first draft of the 
manuscript was written jointly by the study’s prin-
cipal investigator and chair. The academic repre-
sentatives of the executive and steering commit-
tees contributed to subsequent manuscript drafts 
and approved the submission of the final manu-
script for publication. The study’s principal inves-
tigator and chair had full access to all data, veri-
fied their accuracy, and vouch for the fidelity of 
the study to the protocol. The study was approved 
by the national regulatory authority in each partici-
pating country and by the local ethics committee 
or institutional review board at each study center.
Study Patients
Patients with acute coronary syndromes were eli-
gible if they were selected for a final treatment 
strategy of medical management without revas-
cularization within 10 days after the index event. 
Patients with myocardial infarction without ST-
segment elevation had elevated cardiac markers, 
whereas patients with unstable angina with neg-
ative cardiac markers had an ST-segment depres-
sion of more than 1 mm in two or more electro-
cardiographic leads. Patients were required to 
have at least one of four risk criteria: an age of at 
least 60 years, the presence of diabetes mellitus, 
previous myocardial infarction, or previous revas-
cularization with either PCI or coronary-artery 
bypass grafting (CABG). Angiography was not 
required for enrollment, but if such a procedure 
was planned, it had to be performed before ran-
domization. Patients who underwent angiography 
were required to have evidence of coronary disease 
(native coronary stenosis of >30% or previous PCI 
or CABG). Major exclusion criteria included a his-
tory of transient ischemic attack or stroke, PCI or 
CABG within the previous 30 days, renal failure 
requiring dialysis, and concomitant treatment with 
an oral anticoagulant.
From June 27, 2008, through September 12, 
2011, we enrolled 9326 patients at 966 sites in 52 
countries. Across regions, 3090 participants were 
enrolled in Central and Eastern Europe (33.1% of 
the total), 994 in Western Europe and Scandina-
via (10.7%), 1276 in Latin America (13.7%), 752 in 
East Asia (8.1%), 1141 in India (12.2%), 1271 in 
North America (13.6%), 658 in the Mediterranean 
area (7.1%), and 144 in Australia, New Zealand, 
and South Africa (1.5%). A total of 7243 patients 
were younger than 75 years of age (77.7%), where-
as 2083 patients were 75 years of age or older 
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(22.3%). All patients provided written informed 
consent.
Study Treatment
Patients were randomly assigned to receive either 
prasugrel or clopidogrel in a double-blind, double-
dummy fashion with the use of an interactive voice-
response system. Patients who underwent random-
ization within 72 hours after the first medical 
contact without previous clopidogrel treatment 
received a loading dose of 30 mg of prasugrel or 
300 mg of clopidogrel, which was followed by daily 
blinded maintenance administration of a study 
drug. Patients who did not undergo randomiza-
tion within 72 hours were required to be treated 
with open-label clopidogrel before randomization 
and were started on daily maintenance adminis-
tration of a study drug after randomization.
The prasugrel maintenance dose was 10 mg, 
which was adjusted to 5 mg for patients who were 
75 years of age or older or who weighed less 
than 60 kg. The clopidogrel maintenance dose was 
75 mg for all patients. Pharmacokinetic modeling 
from previous trials showed that 5 mg of pra su-
grel in patients weighing less than 60 kg resulted 
in an antiplatelet effect that was similar to that 
for 10 mg in heavier patients.11 The 5-mg dose 
that was used in participants 75 years of age or 
older had not been evaluated in previous out-
comes trials. Concomitant treatment with aspi-
rin was required, and a daily dose of 100 mg or 
less was strongly recommended. Study treatments 
continued for a minimum of 6 months and a 
maximum of 30 months.
End Points
The primary efficacy end point was a composite 
of death from cardiovascular causes, nonfatal myo-
cardial infarction, or nonfatal stroke among pa-
tients under the age of 75 years. Other end points 
have been defined previously.10 Suspected is che-
mic and bleeding end points were evaluated by 
an independent cardiovascular adjudication com-
mittee whose members were unaware of study-
group assignments. Suspected new, nonbenign 
neoplasm end points were adjudicated by an in-
dependent oncology adjudication committee (for 
details, see the Supplementary Appendix).
Bleeding Events
Key bleeding end points were analyzed on the ba-
sis of Global Use of Strategies to Open Occluded 
Coronary Arteries (GUSTO) criteria for severe or 
life-threatening bleeding not related to CABG and 
Thrombolysis in Myocardial Infarction (TIMI) 
criteria for major bleeding not related to CABG.
Statistical Analysis
We estimated that 688 patients with primary ef-
ficacy events would be needed to ensure a power 
of 90% to detect a relative risk reduction of 22% 
between the two study groups among patients 
under the age of 75 years using a two-sided test 
at the 5% significance level. Formal sample-size 
analyses were not performed for patients who 
were 75 years of age or older, since this second-
ary analysis was exploratory, with a previously un-
tested dose of prasugrel (5 mg daily); however, an 
enrollment of more than 2000 patients was tar-
geted. All efficacy analyses were performed on the 
intention-to-treat population.
Testing for the superiority of pra su grel over 
clo pid o grel was done with a two-sided log-rank 
test and stratified according to clo pid o grel status 
at the time of randomization, as described previ-
ously.10 If superiority was established in patients 
under the age of 75 years, then testing for superi-
ority would have been done in a hierarchical man-
ner on the overall patient cohort, stratified accord-
ing to age group. We explored the consistency of 
treatment effect on the primary efficacy end point 
in prespecified subgroups.
Landmark analyses of the primary end point 
were not prespecified. An Andersen–Gill intensity-
model analysis using a robust variance estimate 
was prespecified and performed to account for 
repeated ischemic events among all components 
of the primary end point for the overall period and 
using a time-dependent model with separate haz-
ard ratios before and after 30 days, 6 months, and 
12 months.12
Key bleeding end points were evaluated in pa-
tients who received at least one dose of a study 
drug, with a stratified log-rank test during the 
period from the initiation of the study drug until 
7 days after its discontinuation. New, nonbenign 
neoplasm end points were evaluated in the over-
all population in patients who received at least one 
dose of a study drug.
During systematic audits of study centers, 
four sites (enrolling 120 patients) were found to 
have violated key protocol requirements and Good 
Clinical Practice guidelines. These sites were 
closed, and the administration of study drugs to 
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all patients at those sites was discontinued. The 
executive committee decided to prospectively ex-
clude these patients from all analyses before un-
blinding and database lock.
R esult s
Study Patients
Of 9326 patients who underwent randomization, 
573 did not complete the study; vital status was 
collected on all but 18 patients (Fig. S1 in the 
Supplementary Appendix). The median duration of 
exposure to a study drug was 14.8 months (inter-
quartile range, 8.2 to 23.6). During the follow-up 
period, 76% of patients in the pra su grel group con-
tinued to receive the study drug, as compared with 
78% of those in the clo pid o grel group (P = 0.03). 
The median duration of follow-up for all patients 
in the trial was 17.1 months (interquartile range, 
10.4 to 24.4).
Baseline characteristics were generally balanced 
in the two study groups among patients under the 
age of 75 years and in the overall population (Table 
1). Among patients under the age of 75 years, 
the median time from presentation to the initia-
tion of a study drug was just over 4 days, and 
nearly half the patients underwent angiography 
before randomization.
During follow-up, 571 of the 7243 patients under 
the age of 75 years (7.9%) underwent revasculari-
Table 1. Baseline Characteristics of the Patients.*
Characteristic Age <75 Years Overall Population
Prasugrel
(N = 3620)
Clopidogrel
(N = 3623)
Prasugrel
(N = 4663)
Clopidogrel
(N = 4663)
Age (yr)
Median 62 62 66 66
Interquartile range 56–68 56–68 58–74 59–73
Female sex (%) 36.2 35.6 39.2 39.1
Body weight <60 kg (%) 13.1 12.8 15.2 14.9
Disease classification (%)
NSTEMI 67.8 67.2 70.4 69.4
Unstable angina 32.2 32.8 29.6 30.6
Killip class II to IV on presentation (%) 9.5 10.3 12.1 12.2
Time from presentation until start of study drug (hr)
Median 102 103 108 108
Interquartile range 58–158 60–157 62–160 63–160
Cardiovascular risk factors (%)
Family history of coronary artery disease 31.5 32.1 29.7 31.1
Hypertension 80.3 80.4 81.9 82.0
Hyperlipidemia 58.2 59.7 59.0 59.3
Diabetes mellitus 38.5 39.3 37.7 38.3
Current or recent smoker† 23.3 23.6 19.7 20.2
Cardiovascular disease history (%)
Previous myocardial infarction 43.3 44.8 42.9 43.3
Previous PCI 27.0 29.1 25.6 26.7
Previous CABG 14.6 16.3 15.2 16.1
Previous peripheral arterial disease 6.0 7.3 7.2 7.6
Previous atrial fibrillation 5.9 6.2 7.6 8.0
Previous heart failure 17.1 17.1 17.6 17.6
GRACE risk score‡
Median 114 115 122 121
Interquartile range 101–128 102–128 105–140 106–138
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zation (427 underwent PCI, 170 underwent CABG, 
and 26 underwent both procedures), with a me-
dian time from randomization to first revascular-
ization of 113 days (interquartile range, 40 to 334).
Efficacy
At 30 months, there was no significant between-
group difference in the rate of the primary end 
point among the primary cohort of patients un-
der the age of 75 years (Table 2). At a median 
follow-up of 17 months, the primary end point 
occurred in 13.9% of the pra su grel group and 
16.0% of the clo pid o grel group (hazard ratio in 
the pra su grel group, 0.91; 95% confidence inter-
val [CI], 0.79 to 1.05; P = 0.21) (Fig. 1A). Because 
superiority was not established in this cohort, 
the prespecified testing strategy did not direct fur-
ther superiority testing, but efficacy and safety re-
sults for the overall cohort (all ages) are presented 
for completeness (Tables 2 and 3, and Table S1 and 
Fig. S2 in the Supplementary Appendix). Among 
patients under the age of 75 years, the Kaplan–
Meier curves for the primary end point overlapped 
until approximately 12 months, after which the 
curves diverged. Similar observations were made 
for each of the secondary end points (death from 
cardiovascular causes, all myocardial infarctions, 
and strokes) (Fig. 1B, 1C, and 1D).
Table 1. (Continued.)
Characteristic Age <75 Years Overall Population
Prasugrel
(N = 3620)
Clopidogrel
(N = 3623)
Prasugrel
(N = 4663)
Clopidogrel
(N = 4663)
Creatinine clearance (ml/min)
Median 81 81 73 73
Interquartile range 63–104 63–102 54–97 54–96
Prerandomization clopidogrel stratum (%)§
1 4.2 4.6 4.2 4.4
2 69.3 68.4 69.9 69.8
Time from start of clopidogrel until start of study 
drug for participants in stratum 2 (hr)
Median 103 105 107 108
Interquartile range 64–154 61–153 65–155 63–155
3 26.5 27.0 25.9 25.9
Angiography performed before randomization (%) 42.1 43.1 41.2 41.4
Concomitant medication at randomization (%)
Aspirin
<100 mg/day 34.6 33.5 33.9 32.8
100–250 mg/day 52.2 52.3 53.1 53.2
>250 mg 7.2 8.1 7.0 7.4
Beta-blocker 78.1 77.5 78.3 77.2
ACE inhibitor or angiotensin-receptor blocker 74.9 75.1 75.3 75.4
Statin 83.9 84.0 83.6 83.1
Proton-pump inhibitor 22.9 23.1 25.3 25.0
* For patients under the age of 75 years, significant between-group differences (P<0.05) were observed only for previous 
percutaneous coronary intervention (PCI), previous coronary-artery bypass grafting (CABG), and previous peripheral arte-
rial disease. For the overall population, there were no significant between-group differences. ACE denotes angiotensin-
converting enzyme, and NSTEMI non–ST-segment elevation myocardial infarction.
† This category was defined as cigarette smoking within 30 days before randomization.
‡ Global Registry of Acute Coronary Events (GRACE) risk scores range from 0 to 372, with a score of 140 or more consid-
ered to indicate high risk.
§ Clopidogrel strata are defined as follows: stratum 1, no clopidogrel administered before randomization, with randomiza-
tion occurring within 72 hours after the first medical contact; stratum 2, a loading dose of clopidogrel (300 to 600 mg) 
administered for the index event, followed by a daily clopidogrel maintenance dose (75 mg) until the day of randomiza-
tion; and stratum 3, a daily maintenance dose of clopidogrel (75 mg), starting at least 5 days before presentation for 
the index event and continuing until the day of randomization.
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Because we observed a divergence of treatment 
effect among patients under the age of 75 years 
after the prespecified 12-month time point, we 
tested the difference in treatment effect between 
the first 12 months and subsequent months in a 
post hoc analysis using a time-dependent Cox 
proportional-hazards model; in this analysis, the 
time period and the interaction between the time 
period and treatment were time-dependent factors. 
The frequency of the primary end point through 
12 months was similar among study groups, with 
a weak trend toward a reduced risk in the pra su grel 
group after 12 months (P = 0.07 for interaction) 
(Fig. 1A).
The frequency of the primary end point in the 
two study groups did not differ significantly 
among prespecified subgroups of patients who 
were under the age of 75 years, but an interaction 
with pra su grel treatment was apparent in cur-
rent or recent smokers, those who underwent an-
giography before randomization, and those tak-
ing a proton-pump inhibitor at randomization 
(Fig. 2).
The prespecified analysis that was performed 
to account for multiple recurrent ischemic events 
suggested a lower risk among patients under the 
age of 75 years in the pra su grel group (hazard 
ratio, 0.85; 95% CI, 0.72 to 1.00; P = 0.04). Among 
patients who had an ischemic event, 364 patients 
in the pra su grel group (10.1%) had at least one 
ischemic event, as compared with 397 patients in 
the clo pid o grel group (11.0%), whereas 77 (2.1%) 
versus 109 (3.0%) had at least two recurrent is-
che mic events, and 18 (0.5%) versus 24 (0.7%) had 
at least three recurrent is che mic events, respec-
tively. (Data on the breakdown of component end 
points per category of number of recurrent events 
are provided in Table S2 in the Supplementary 
Appendix.) In the time-dependent analysis of re-
current events using a 12-month landmark time 
point, there was a significant interaction with 
treatment and time (P = 0.02). The risk of re-
current is che mic events in the pra su grel group 
was lower after 12 months (hazard ratio for 
<12 months, 0.94 [95% CI, 0.79 to 1.12], vs. 
hazard ratio for ≥12 months, 0.64 [95% CI, 0.48 
to 0.86]).
Safety
At 30 months, the key bleeding end points of non–
CABG-related severe or life-threatening events 
(according to GUSTO criteria) and major bleeding T
ab
le
 2
. E
ff
ic
ac
y 
O
ut
co
m
es
 a
t 3
0 
M
on
th
s.
*
O
ut
co
m
e
A
ge
 <
75
 Y
ea
rs
O
ve
ra
ll 
Po
pu
la
tio
n
Pr
as
ug
re
l (
N
 =
 3
62
0)
C
lo
pi
do
gr
el
 (
N
 =
 3
62
3)
H
az
ar
d 
R
at
io
(9
5%
 C
I)
P 
V
al
ue
Pr
as
ug
re
l (
N
 =
 4
66
3)
C
lo
pi
do
gr
el
 (
N
 =
 4
66
3)
H
az
ar
d 
R
at
io
(9
5%
 C
I)
P 
V
al
ue
Pa
tie
nt
s 
w
ith
 
Ev
en
t
Ev
en
t R
at
e
at
 3
0 
M
o
Pa
tie
nt
s 
w
ith
 
Ev
en
t
Ev
en
t R
at
e
at
 3
0 
M
o
Pa
tie
nt
s 
w
ith
 
Ev
en
t
Ev
en
t R
at
e 
 
at
 3
0 
M
o
Pa
tie
nt
s 
w
ith
 
Ev
en
t
Ev
en
t R
at
e 
 
at
 3
0 
M
o
no
. (
%
)
%
 (
95
%
 C
I)
no
. (
%
)
%
 (
95
%
 C
I)
no
. (
%
)
%
 (
95
%
 C
I)
no
. (
%
)
%
 (
95
%
 C
I)
C
ar
di
ov
as
cu
la
r 
de
at
h,
 
m
yo
ca
rd
ia
l  
in
fa
rc
tio
n,
 o
r 
st
ro
ke
36
4 
(1
0.
1)
13
.9
(1
2.
2–
15
.6
)
39
7 
(1
1.
0)
16
.0
(1
4.
0–
18
.1
)
0.
91
(0
.7
9–
1.
05
)
0.
21
62
1 
(1
3.
3)
18
.7
(1
7.
0–
20
.4
)
64
8 
(1
3.
9)
20
.3
(1
8.
5–
22
.2
)
0.
96
(0
.8
6–
1.
07
)
0.
45
C
ar
di
ov
as
cu
la
r 
de
at
h
16
7 
(4
.6
)
6.
6
(5
.3
–7
.9
)
17
9 
(4
.9
)
6.
8
(5
.7
–7
.9
)
0.
93
(0
.7
5–
1.
15
)
0.
48
30
8 
(6
.6
)
9.
9
(8
.5
–1
1.
3)
33
0 
(7
.1
)
10
.2
(9
.0
–1
1.
4)
0.
93
(0
.8
0–
1.
09
)
0.
38
M
yo
ca
rd
ia
l i
nf
ar
ct
io
n
21
7 
(6
.0
)
8.
3
(7
.1
–9
.6
)
24
4 
(6
.7
)
10
.5
(8
.6
–1
2.
4)
0.
89
(0
.7
4–
1.
07
)
0.
21
36
1 
(7
.7
)
10
.7
(9
.5
–1
2.
0)
37
6 
(8
.1
)
12
.3
(1
0.
6–
14
.0
)
0.
96
(0
.8
3–
1.
11
)
0.
58
St
ro
ke
31
 (
0.
9)
1.
5
(0
.6
–2
.4
)
46
 (
1.
3)
2.
2
(1
.4
–2
.9
)
0.
67
(0
.4
2–
1.
06
)
0.
08
62
 (
1.
3)
2.
2
(1
.4
–3
.0
)
69
 (
1.
5)
2.
6
(1
.9
–3
.3
)
0.
89
(0
.6
3–
1.
26
)
0.
52
D
ea
th
 fr
om
 a
ny
 c
au
se
20
8 
(5
.7
)
7.
8
(6
.5
–9
.1
)
21
8 
(6
.0
)
8.
1
(7
.0
–9
.3
)
0.
96
(0
.7
9–
1.
16
)
0.
63
38
5 
(8
.3
)
11
.6
(1
0.
3–
13
.0
)
40
9 
(8
.8
)
12
.2
(1
0.
9–
13
.4
)
0.
94
(0
.8
2–
1.
08
)
0.
40
* 
H
az
ar
d 
ra
tio
s 
an
d 
P 
va
lu
es
 fo
r 
th
e 
co
m
pa
ri
so
n 
be
tw
ee
n 
pr
as
ug
re
l a
nd
 c
lo
pi
do
gr
el
 a
re
 b
as
ed
 o
n 
lo
g-
ra
nk
 t
es
t 
co
m
pa
ri
ng
 K
ap
la
n–
M
ei
er
 e
st
im
at
es
 t
hr
ou
gh
 3
0 
m
on
th
s 
w
ith
 s
tr
at
ifi
ca
tio
n 
ac
co
rd
in
g 
to
 c
lo
pi
do
gr
el
 s
ta
tu
s 
at
 r
an
do
m
iz
at
io
n 
(f
or
 p
at
ie
nt
s 
<7
5 
ye
ar
s 
of
 a
ge
 a
nd
 t
he
 o
ve
ra
ll 
po
pu
la
tio
n)
 a
nd
 a
ge
 g
ro
up
 (
fo
r 
th
e 
ov
er
al
l p
op
ul
at
io
n)
.
The New England Journal of Medicine 
Downloaded from nejm.org on May 31, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Pr asugrel vs. Clopidogrel for Acute Coronary Syndromes
n engl j med 367;14 nejm.org october 4, 2012 1303
Pr
im
ar
y 
En
d 
Po
in
t (
%
)
100
80
60
40
20
0
0 180 360 540 720 900
20
15
10
5
0
0 180 360 540 720 900
Days
C All Myocardial Infarctions
A Primary End Point
No. at Risk, Primary
Efficacy End Point
Prasugrel
Clopidogrel
3620
3623
3248
3244
2359
2390
1611
1596
953
946
389
399
C
ar
di
ov
as
cu
la
r 
D
ea
th
 (%
)
100
80
60
40
20
0
0 180 360 540 720 900
Days
B Death from Cardiovascular Causes
No. at Risk
Prasugrel
Clopidogrel
3620
3623
3350
3361
2481
2504
1719
1703
1029
1024
429
428
No. at Risk, Major
Bleeding
Prasugrel
Clopidogrel
3590
3590
3072
3116
2244
2303
1499
1552
885
925
427
425
A
ll 
M
yo
ca
rd
ia
l I
nf
ar
ct
io
ns
 (%
)
100
80
60
40
20
0
0 180 360 540 720 900
Days
No. at Risk
Prasugrel
Clopidogrel
3620
3623
3257
3255
2369
2404
1620
1611
959
955
392
402
A
ll 
St
ro
ke
s 
(%
)
100
80
60
40
20
0
0 180 360 540 720 900
Days
D All Strokes
No. at Risk
Prasugrel
Clopidogrel
3620
3623
3338
3346
2467
2486
1706
1684
1020
1012
422
424
10
8
6
4
2
0
0 180 360 540 720 900
12
10
8
6
4
2
0
0 180 360 540 720 900
5
4
3
2
1
0
0 180 360 540 720 900
Primary Efficacy
End Point
TIMI Major Bleeding 
16.0
Clopidogrel 6.8
6.6
2.2
1.5
Clopidogrel
Prasugrel
Clopidogrel
ClopidogrelPrasugrel
Prasugrel
Prasugrel
2.1
1.5
13.9
10.5
8.3
Figure 1. Cumulative Kaplan–Meier Estimates of Key Study End Points in Patients under the Age of 75 Years during 30 Months of Follow-up.
Panel A shows data for the primary efficacy end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal 
stroke (top curves) and the key bleeding end point of TIMI major bleeding not related to coronary-artery bypass grafting (bottom curves). 
The inset shows the same data on an enlarged y axis. The hazard ratio for the comparison between prasugrel and clopidogrel for the  
primary efficacy end point through the entire treatment period of 30 months was 0.91 (95% CI, 0.79 to 1.05; P = 0.21). The hazard ratio  
for the key bleeding end point was 1.31 (95% CI, 0.81 to 2.11; P = 0.27). Hazard ratios and 95% confidence intervals for the time period of  
12 months or less versus the time period of more than 12 months comparing prasugrel with clopidogrel for the primary efficacy end 
point were 0.99 (95% CI, 0.84 to 1.16) versus 0.72 (95% CI, 0.54 to 0.97) (P = 0.07 for interaction). Panel B shows data for death for car-
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(according to TIMI criteria) occurred with similar 
frequency among patients under the age of 75 years 
in the two study groups (Table 3). The Kaplan–
Meier curves for TIMI major bleeding appeared to 
diverge slightly between study groups after 30 days 
but remained parallel thereafter (Fig. 1A). The only 
subgroup in which there was a significant treat-
ment interaction for TIMI major bleeding was pa-
tients receiving a reduced dose of aspirin (Fig. S3 
in the Supplementary Appendix). Curves for bleed-
ing events in the overall population remained 
parallel throughout the study (Fig. S2 in the Sup-
plementary Appendix). TIMI life-threatening, fa-
tal, or intracranial bleeding occurred infrequently, 
and rates were balanced in the two study groups, 
both in patients under the age of 75 years and in 
the overall population. Among the younger pa-
tients, rates of non–CABG-related severe or life-
threatening or moderate bleeding (GUSTO crite-
ria) and major or minor bleeding (TIMI criteria) 
were higher in the pra su grel group.
The frequency of new, nonbenign neoplasms in 
the overall treated population did not differ sig-
nificantly between the pra su grel group and the 
clo pid o grel group (1.9% vs. 1.8%, P = 0.79); simi-
lar findings were observed among treated patients 
with no history of cancer or a history of previous 
cancer that had been cured before randomization 
(1.8% vs. 1.7%, P = 0.79).
The incidence of common (>1%) nonhemor-
rhagic serious adverse events was balanced be-
tween the two study groups among patients un-
der the age of 75 years, and the only significant 
difference observed was a higher rate of heart 
failure in the clo pid o grel group (Table S3 in the 
Supplementary Appendix).
Discussion
In this large, randomized trial of prolonged treat-
ment with pra su grel, as compared with clo pid o grel, 
in patients with unstable angina or myocardial 
infarction without ST-segment elevation who did 
not undergo revascularization, we did not find a 
reduction in the rate of major cardiovascular events 
in the pra su grel group. The more intense platelet 
inhibition with pra su grel was confirmed by the ob-
servation of higher rates of minor or moderate 
bleeding among patients receiving pra su grel, al-
though there was no significant increase in the 
rate of severe, major, or life-threatening bleeding 
despite treatment for up to 30 months.
An unexpected time-dependent divergence of 
treatment effect was observed after 12 months of 
therapy among patients under the age of 75 years. 
When evaluated before and after 12 months, the 
interaction of the treatment effect of pra su grel for 
the time to the first event was weak, but the late 
separation of the event curves was consistent for 
both primary and component end points, an ob-
servation that was also apparent in the analysis of 
multiple recurrent is che mic events. The reasons for 
this finding remain uncertain, since there have 
been few studies focusing on high-risk patients 
who did not undergo revascularization. Such pa-
tients would be expected to have a more linear and 
sustained risk of is che mic events that is not pro-
voked by the use of revascularization procedures 
during the index hospitalization. A prospective 
natural-history study of coronary atherosclerosis 
after an acute coronary event supported this con-
cept, since it showed a near-linear event rate over a 
3-year period, with almost 50% of later cardiovas-
cular events occurring in nontarget vessels.13 Fur-
thermore, platelet reactivity may be amplified after 
revascularization procedures, so an early response 
to intensified platelet inhibition may not be ap-
parent in patients receiving medical therapy, as has 
been shown in patients undergoing invasive pro-
cedures.8,9,14 Consequently, it is possible that a 
median follow-up period of 17 months was not 
long enough to explore the divergence of is che mic 
events in patients receiving medical therapy alone.
The significant treatment effect of pra su grel 
on multiple recurrent is che mic events in this 
study is consistent with findings from the Trial 
to Assess Improvement in Therapeutic Outcomes 
by Optimizing Platelet Inhibition with Pra su grel 
(TRITON), in which the relative risk of recurrent 
is che mic events was reduced by 30% in the pra-
su grel group among patients treated with PCI.15 
The majority of the effect of pra su grel on recur-
rent is che mic events occurred later in both trials, 
but the degree of late separation appeared to be 
more pronounced in our study. Although this 
observation is exploratory, it raises the question 
of whether investigation of the multiplicity of 
is che mic events is warranted in future secondary-
prevention trials, rather than solely analyzing 
the time to the first event, as has been traditional 
in studies involving patients who have had an 
acute coronary event.
This trial had a long follow-up (up to 2.5 years) 
among patients receiving pra su grel after an acute 
The New England Journal of Medicine 
Downloaded from nejm.org on May 31, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;14 nejm.org october 4, 20121306
1.0 1.5 2.0
Clopidogrel BetterPrasugrel Better
Overall results
Age
<65 yr
≥65 yr
Sex
Female
Male
Weight
<60 kg
≥60 kg
GRACE risk score
<100
100–140
>140
Disease classification
Unstable angina
NSTEMI
Diabetes mellitus
Yes
No
Current or recent smoker
Yes
No
Previous myocardial infarction
Yes
No
Previous PCI
Yes
No
Previous CABG
Yes
No
Previous PAD
Yes
No
Creatinine clearance
<30 ml/min
30–60 ml/min
>60 ml/min
Angiography before randomization
Yes
No
Aspirin dose at randomization
<100 mg/day
≥100 mg/day
PPI at randomization
Yes
No
Clopidogrel stratum
Stratum 1
Stratum 2
Stratum 3
Region
Central and Eastern Europe
East Asia
India
Latin America
Mediterranean area
North America
Western Europe and Scandinavia
Australia, New Zealand, and
South Africa
Total No.
of Patients Hazard Ratio (95% CI)ClopidogrelPrasugrelCharacteristic
1.01 (0.84–1.20)
0.91 (0.71–1.18)
0.90 (0.74–1.08)
0.70 (0.53–0.92)
1.01 (0.86–1.20)
1.16 (0.59–2.30)
0.91 (0.76–1.08)
0.90 (0.69–1.17)
1.06 (0.82–1.39)
1.19 (0.75–1.89)
0.86 (0.57–1.30)
0.81 (0.56–1.17)
0.58 (0.32–1.05)
0.89 (0.64–1.24)
0.88 (0.53–1.45)
0.68 (0.24–1.90)
0.88 (0.73–1.05)
1.14 (0.88–1.49)
0.99 (0.67–1.47)
0.92 (0.78–1.08)
0.93 (0.69–1.26)
0.96 (0.81–1.14)
0.95 (0.77–1.17)
0.82 (0.63–1.06)
0.54 (0.39–0.74)
1.06 (0.90–1.24)
0.90 (0.74–1.10)
0.93 (0.80–1.08)
0.68 (0.33–1.41)
0.77 (0.61–0.98)
0.94 (0.77–1.16)
0.90 (0.73–1.09)
0.92 (0.67–1.26)
0.91 (0.78–1.07)
0.86 (0.56–1.33)
0.91 (0.76–1.08)
1.19 (0.86–1.63)
0.92 (0.78–1.07)
0.91 (0.64–1.29)
0.86 (0.72–1.03)
1.02 (0.80–1.29)
1.02 (0.84–1.24)
0.91 (0.79–1.05)
0.5
0.82 (0.67–1.01)
P Value for
Interaction
13.9
11.0
18.2
14.7
13.4
15.5
13.6
7.6
14.7
26.2
9.7
15.7
17.8
11.5
11.7
14.6
16.3
12.1
14.6
13.7
19.5
12.9
28.4
12.9
28.1
22.7
11.9
10.7
16.3
13.4
13.7
14.6
13.7
13.1
13.8
14.2
12.9
18.7
10.3
13.8
10.6
19.4
10.5
12.8
16.0
14.7
18.0
14.8
16.6
22.4
15.1
9.1
17.2
23.5
11.1
18.2
20.4
13.2
20.8
14.6
19.0
13.3
17.2
15.6
22.1
14.8
27.2
15.0
47.5
23.7
13.6
14.9
16.7
15.9
15.8
23.8
13.6
14.7
16.1
16.2
13.1
16.0
16.6
16.2
14.0
21.1
14.5
19.0
7243
4327
2916
2599
4644
939
6300
1534
4520
779
2356
4887
2811
4414
1566
5614
3168
4023
2022
5189
1115
6113
472
6657
105
1407
5432
3085
4158
2365
4295
1666
5577
320
4984
1939
2429
571
1021
968
527
995
630
102
0.14
0.29
0.96
0.32
0.97
0.71
<0.001
0.76
0.32
0.94
0.77
0.17
0.08
0.91
0.02
0.78
0.58
event rate at 30 mo (%)
The New England Journal of Medicine 
Downloaded from nejm.org on May 31, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Pr asugrel vs. Clopidogrel for Acute Coronary Syndromes
n engl j med 367;14 nejm.org october 4, 2012 1307
coronary event in a population at high risk for 
major bleeding events. In TRITON, more serious 
or life-threatening bleeding events were seen in 
the pra su grel group,15 a finding that was not ob-
served in our study. The risk of major bleeding 
was low and was similar in the two study groups, 
but the pra su grel dose was adjusted for patients 
who were 75 years of age or older and for those 
weighing less than 60 kg in order to mitigate 
such risks. Nonetheless, a biologic effect through-
out the period of pra su grel exposure is supported 
by the increased frequency of minor or moderate 
bleeding that was observed in this group. Finally, 
the prospective, systematic surveillance and rigor-
ous adjudication of new, nonbenign neoplasms in 
our study showed no increase in the risk of neo-
plasm development with sustained exposure to 
pra su grel for up to 2.5 years.
Prasugrel was not shown to be superior to 
clopidogrel for reducing the primary end point 
during 2.5 years of follow-up after a coronary event 
in patients receiving medical therapy without 
planned revascularization, even though signs of 
intensified platelet inhibition were observed in the 
pra su grel group. The optimal treatment duration 
and intensity of P2Y12 inhibition after a coronary 
event for patients who do not undergo revascular-
ization remain uncertain. However, our findings 
highlight the need for further study of differ-
ences in the response to intensified platelet inhi-
bition for patients receiving medical therapy with-
out revascularization, as compared with those 
undergoing revascularization, for treatment of an 
index cardiac event.
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